Ansun Biopharma

Ansun Biopharma is a privately held, clinical-stage biopharmaceutical company headquartered in the Sorrento Valley district of San Diego, California, founded in 2003 by virologists and molecular biologists and led by CEO Dr. Nancy Chang. Rather than targeting viruses directly, Ansun develops host-directed immuno-biologic therapies built on a recombinant sialidase platform. Its lead candidate, DAS181 (Ansun-181), is a multi-function sialidase fusion protein that removes the sialic acid receptors respiratory viruses use to enter host cells, and has been studied in parainfluenza virus (PIV), severe influenza, human metapneumovirus and COVID-19 in immunocompromised and hospitalized patients. The company also advances earlier-stage programs in oncology and autoimmune disease from the same sialidase platform. Ansun is a drug developer, not a software vendor: it publishes a corporate WordPress site covering its pipeline, research and technologies, publications, intellectual property, investors, news and careers, and exposes no public API, SDK, developer portal or machine-readable specification.

Ansun Biopharma is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Biopharmaceutical, Life Sciences, and Clinical Trials.

Ansun Biopharma’s developer surface includes engineering blog and 9 more developer resources.

🌐 Visit website 📡 Source on GitHub

6.4/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyBiopharmaceuticalLife SciencesClinical TrialsAntiviralsHealthDrug DevelopmentSan Diego

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 6.4/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.4 / 17

Commercial Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Governance 0.0 / 10

Discoverability 4.9 / 9

Regulatory Posture 1.1 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/ansun-biopharma: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Company 6

The organization behind the API

Website

Blog

BlogRSS

About

Careers

Investors

Other 1

Properties that don't map to a standard resource type

SecondaryMarket

SecondaryMarket

Source (apis.yml)

aid: ansun-biopharma
name: Ansun Biopharma
description: 'Ansun Biopharma is a privately held, clinical-stage biopharmaceutical company headquartered in the Sorrento
  Valley district of San Diego, California, founded in 2003 by virologists and molecular biologists and led by CEO Dr. Nancy
  Chang. Rather than targeting viruses directly, Ansun develops host-directed immuno-biologic therapies built on a recombinant
  sialidase platform. Its lead candidate, DAS181 (Ansun-181), is a multi-function sialidase fusion protein that removes the
  sialic acid receptors respiratory viruses use to enter host cells, and has been studied in parainfluenza virus (PIV), severe
  influenza, human metapneumovirus and COVID-19 in immunocompromised and hospitalized patients. The company also advances
  earlier-stage programs in oncology and autoimmune disease from the same sialidase platform. Ansun is a drug developer, not
  a software vendor: it publishes a corporate WordPress site covering its pipeline, research and technologies, publications,
  intellectual property, investors, news and careers, and exposes no public API, SDK, developer portal or machine-readable
  specification.'
url: https://raw.githubusercontent.com/api-evangelist/ansun-biopharma/refs/heads/main/apis.yml
image: https://www.ansunbiopharma.com/wp-content/uploads/2020/06/ansun-bio-logo-3.png
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Biopharmaceutical
- Life Sciences
- Clinical Trials
- Antivirals
- Health
- Drug Development
- San Diego
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/ansun-biopharma-domain-security.yml
- type: LLMsTxt
  url: llms/ansun-biopharma-llms.txt
- type: Website
  url: https://www.ansunbiopharma.com/
- type: Blog
  url: https://www.ansunbiopharma.com/news/
- type: BlogRSS
  url: https://www.ansunbiopharma.com/feed/
- type: About
  url: https://www.ansunbiopharma.com/about/who-we-are/
- type: Contact
  url: https://www.ansunbiopharma.com/contact/
- type: Careers
  url: https://www.ansunbiopharma.com/careers/career-opportunities/
- type: Investors
  url: https://www.ansunbiopharma.com/investors/
- type: SecondaryMarket
  url: https://forgeglobal.com/ansun-biopharma_stock/
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Ansun Biopharma is a 25-person clinical-stage drug developer whose entire public site is a 24-page WordPress brochure
    about the DAS181 sialidase pipeline — there is no developer section, and every spec and .well-known path probed on ansunbiopharma.com
    returned 404 while api. and developer. subdomains do not resolve.
  evidence:
  - url: https://www.ansunbiopharma.com/developers
    status: 404
  - url: https://www.ansunbiopharma.com/openapi.json
    status: 404
  - url: https://www.ansunbiopharma.com/.well-known/agent-card.json
    status: 404
  - url: https://www.ansunbiopharma.com/sitemap.xml
    status: 200
  checked: '2026-08-06'